• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23378 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2012     HAYES, Inc. Ryanodine receptor 1 (RYR1) testing for malignant hyperthermia susceptibility (MHS)
2008     NIHR Horizon Scanning Centre (NIHR HSC) S-1 for advanced gastric cancer - first line therapy
2002     Agency for Healthcare Research and Quality (AHRQ) S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease
2013     HAYES, Inc. S-ICD (Subcutaneous Implantable Cardioverter Defibrillator; Boston Scientific Corp.) for prevention of sudden cardiac death
2022     National Institute for Health and Care Excellence (NICE) Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies. NICE technology appraisal guidance 819
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Sacral nerve stimulation device for urinary incontinence
2004     National Institute for Clinical Excellence (NICE) Sacral nerve stimulation for faecal incontinence
2005     Medical Services Advisory Committee (MSAC) Sacral nerve stimulation for faecal incontinence
2003     National Institute for Clinical Excellence (NICE) Sacral nerve stimulation for faecal incontinence
2015     National Institute for Health and Care Excellence (NICE) Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. NICE interventional procedures guidance 536
2000     Medical Services Advisory Committee (MSAC) Sacral nerve stimulation for refractory urinary urge incontinence or urinary retention
2004     National Institute for Clinical Excellence (NICE) Sacral nerve stimulation for urge incontinence and urgency-frequency
2003     National Institute for Clinical Excellence (NICE) Sacral nerve stimulation for urge incontinence and urgency-frequency
2004     National Institute for Health and Care Excellence (NICE) Sacral nerve stimulation for urge incontinence and urgency-frequency. NICE interventional procedures guidance 64
2008     Medical Services Advisory Committee (MSAC) Sacral nerve stimulation for urinary indications
2005     Medical Advisory Secretariat (MAS) Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-based analysis
2007     Centre Hospitalier de l'Universite de Montreal(CHUM) Sacral nerve stimulation in fecal incontinence
2018     Health Technology Wales (HTW) Sacral nerve stimulation to treat faecal incontinence that cannot be controlled with conservative management
2021     NIHR Health Technology Assessment programme Sacral nerve stimulation versus the magnetic sphincter augmentation device for adult faecal incontinence: the SaFaRI RCT
2017     National Institute for Health and Care Excellence (NICE) Sacrocolpopexy using mesh to repair vaginal vault prolapse. NICE interventional procedures guidance 583
2017     National Institute for Health and Care Excellence (NICE) Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse. NICE interventional procedures guidance 577
2012     HAYES, Inc. Sacroiliac joint fusion for the treatment of adult low back pain
2008     HAYES, Inc. Sacroiliac joint fusion for the treatment of adult low back pain
2011     HAYES, Inc. Sacroiliac joint fusion for treatment of adult low back pain
2014     Andalusian Health Technology Assessment Area (AETSA) Sacroiliac joint fusion. Open versus minimally invasive surgery.
2014     HAYES, Inc. Sacroiliac joint injections with corticosteroids for treatment of chronic low back pain
2016     HAYES, Inc. Sacroiliac joint injections with corticosteroids for treatment of chronic low back pain
2008     HAYES, Inc. Sacroiliac joint injections with corticosteroids for treatment of chronic low back pain
2004     NIHR Horizon Scanning Centre (NIHR HSC) Sacrosidase (Sucraid) for congenital sucrase-isomaltase deficiency - horizon scanning review
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Sacubitril in combination with valsartan for chronic heart failure
2016     National Institute for Health and Care Excellence (NICE) Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 388
2016     HAYES, Inc. Sacubitril-valsartan (Entresto) for heart failure
2022     Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2020     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Safe surgery during the coronavirus disease 2019 crisis
2014     NIHR Horizon Scanning Centre (NIHR HSC) SafePlace for the peripheral insertion of central venous catheters in infants
2024     NIHR Health Services and Delivery Research programme Safer and more efficient vital signs monitoring protocols to identify the deteriorating patients in the general hospital ward: an observational study
2021     NIHR Public Health Research (PHR) programme Safetxt:A randomised controlled trial of an intervention delivered by mobile phone messaging to reduce sexually transmitted infections (STI) by increasing sexual health precaution behaviours in young people.
2020     The Regional Health Technology Assessment Centre (HTA-centrum) Safety and effectiveness of outpatient compared with inpatient induction of labour in singleton uncomplicated pregnancies
2016     Andalusian Health Technology Assessment Area (AETSA) Safety and effectiveness of perfusion machine in solid organ transplantation
2011     Penn Medicine Center for Evidence-based Practice (CEP) Safety and effectiveness of rhBMP-2 (infuse bone graft) for spinal fusion: 2011 update
2003     Institute for Clinical Effectiveness and Health Policy (IECS) Safety and efficacy of cochlear implants
2007     Institute of Health Economics (IHE) Safety and efficacy of inhaled nitric oxide in the management of hypoxemic respiratory failure in adults with acute respiratory distress syndrome
2002     Centre for Clinical Effectiveness (CCE) Safety and efficacy of percutaneous vertebroplasty in symptomatic osteoporotic vertebral compression fractures
2007     Quality Improvement Scotland (NHS QIS ) Safety and risk associated with free standing midwife led maternity units (MLMU)
2012     Scottish Health Technologies Group (SHTG) Safety and risk associated with free standing midwife led maternity units. This evidence note updates evidence note 18 published in August 2007
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Safety of air vents in psychiatric units in a hospital setting: a review of the clinical evidence and guidelines
1999     Health Council of the Netherlands Gezondheidsraad (GR) Safety of amino acid supplementation
2022     NIHR Health Services and Delivery Research programme Safety of disinvestment in mid- to late-term follow-up post primary hip and knee replacement: the UK SAFE evidence synthesis and recommendations
1992     Health Council of the Netherlands Gezondheidsraad (GR) Safety of food produced by new biotechnology
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Safety of leflunomide and methotrexate as combination therapy for rheumatoid arthritis: a review of the clinical evidence
2011     Agency for Healthcare Research and Quality (AHRQ) Safety of probiotics used to reduce risk and prevent or treat disease
2014     Penn Medicine Center for Evidence-based Practice (CEP) Safety of renal biopsy for patients taking aspirin
2014     Agency for Healthcare Research and Quality (AHRQ) Safety of vaccines used for routine immunization in the United States
2021     Agency for Healthcare Research and Quality (AHRQ) Safety of vaccines used for routine immunization in the United States: an update
2020     Norwegian Institute of Public Health (NIPH) Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia: a health technology assessment
2003     Andalusian Health Technology Assessment Area (AETSA) Safety, efficacy and efficiency of transmyocardial laser. Update of evidence-Systematic Review.
2011     NIHR Horizon Scanning Centre (NIHR HSC) Safinamide for early stage parkinson's disease - adjuvant therapy
2011     NIHR Horizon Scanning Centre (NIHR HSC) Safinamide for mid-to-late stage parkinson's disease - adjuvant therapy
2015     NIHR Health Technology Assessment programme Saline in Acute Bronchiolitis RCT and Economic evaluation: hypertonic saline in acute bronchiolitis - randomised controlled trial and systematic review
1999     Medical Services Advisory Committee (MSAC) Saline infusion sonohysterography
2005     HAYES, Inc. Salivary estriol test for preterm labor
2013     HAYES, Inc. Salivary hormone testing for menopausal women
2000     Health Council of the Netherlands Gezondheidsraad (GR) Salt intake and hypertension
1999     Medical Services Advisory Committee (MSAC) Samarium-153-lexidronam for bone pain due to skeletal metastases
2022     WorkSafeBC SANUWAVE therapy for wound healing
2016     NIHR Horizon Scanning Centre (NIHR HSC) Sapacitabine - acute myeloid leukaemia: patients ≥70 years of age; not candidates for standard intensive therapy – first line
2006     NIHR Horizon Scanning Centre (NIHR HSC) Sapropterin dihydrochloride for phenylketonuria: horizon scanning technology briefing
2021     National Institute for Health and Care Excellence (NICE) Sapropterin for treating hyperphenylalaninaemia in phenylketonuria. NICE technology appraisal guidance 729
2012     NIHR Horizon Scanning Centre (NIHR HSC) SAR-302503 for myelofibrosis – first line
2012     NIHR Horizon Scanning Centre (NIHR HSC) SAR236553/REGN727 for the reduction of elevated total cholesterol and low density lipoprotein cholesterol
2008     NIHR Horizon Scanning Centre (NIHR HSC) Saredutant (SR-48968) for depression and anxiety
2015     NIHR Horizon Scanning Centre (NIHR HSC) Sarilumab for moderate to severe active rheumatoid arthritis
2017     National Institute for Health and Care Excellence (NICE) Sarilumab for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 485
2021     European Network for Health Technology Assessment (EUnetHTA) Sarilumab for the treatment of COVID-19
2022     WorkSafeBC Satir brief transformational therapy as treatment for trauma-related disorders including PTSD
2005     NIHR Health Technology Assessment programme Satisfaction in Life for Children With Own Report Measures (SILCWORM)
2009     NIHR Horizon Scanning Centre (NIHR HSC) Sativex for adults experiencing pain from cancer
2009     NIHR Horizon Scanning Centre (NIHR HSC) Sativex for spasticity in multiple sclerosis
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Sativex for the management of multiple sclerosis symptoms
2024     National Institute for Health and Care Excellence (NICE) Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal). NICE technology appraisal guidance 960
2006     NIHR Horizon Scanning Centre (NIHR HSC) Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing
2004     NIHR Horizon Scanning Centre (NIHR HSC) Satraplatin for second-line treatment of hormone-refractory prostate cancer - horizon scanning review
2009     HAYES, Inc. Saw palmetto for benign prostatic hyperplasia
2008     NIHR Horizon Scanning Centre (NIHR HSC) Saxagliptin (BMS 477118) for type 2 diabetes
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Saxagliptin (Onglyza®)
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Saxagliptin (Onglyza®)
2013     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Saxagliptin (Onglyza®)
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin + metformin (Komboglyze — AstraZeneca) indication: type 2 diabetes mellitus
2008     Adelaide Health Technology Assessment (AHTA) Scalable Medical Alert Response Technology (SMART) for monitoring emergency department patients
2000     West Midlands Health Technology Assessment Collaboration (WMHTAC) Scale and polish for chronic periodontal disease
2013     Penn Medicine Center for Evidence-based Practice (CEP) Scales for assessing inpatients' risk of accidental falls
2018     Penn Medicine Center for Evidence-based Practice (CEP) Scales for Assessing Patients Receiving Moderate Sedation
2005     The Swedish Council on Health Technology Assessment (SBU) Scalp cooling to prevent chemotherapy-induced hair loss - early assessment briefs (Alert)
2007     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Scalpel safety in the operative setting: a systematic review
1996     Alberta Heritage Foundation for Medical Research (AHFMR) Scanning laser ophthalmoscope for diagnosis and monitoring of glaucoma
2002     HAYES, Inc. Scanning laser polarimetry for detection and monitoring of glaucoma
2008     HAYES, Inc. Scanning laser polarimetry for detection and monitoring of glaucoma
2022     Agency for Healthcare Research and Quality (AHRQ) Schedule of visits and televisits for routine antenatal care
1993     Danish Institute for Health Services Research (DSI) Schizophrenia, Consensus statement